NASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free PALI Stock Alerts $0.40 +0.00 (+0.96%) (As of 05:22 PM ET) Add Compare Share Share Today's Range$0.39▼$0.4250-Day Range$0.36▼$0.9652-Week Range$0.36▼$3.65Volume131,322 shsAverage Volume2.69 million shsMarket Capitalization$3.70 millionP/E RatioN/ADividend YieldN/APrice Target$8.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Palisade Bio alerts: Email Address Palisade Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,092.4% Upside$8.75 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 6 Articles This WeekInsider TradingAcquiring Shares$6,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.34 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.75, Palisade Bio has a forecasted upside of 2,092.4% from its current price of $0.40.Amount of Analyst CoveragePalisade Bio has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.50% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 41.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PALI. Previous Next 3.4 News and Social Media Coverage News SentimentPalisade Bio has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Palisade Bio this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat Follows2 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.24% of the stock of Palisade Bio is held by insiders.Percentage Held by InstitutionsOnly 11.79% of the stock of Palisade Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Palisade Bio Stock (NASDAQ:PALI)Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.Read More PALI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PALI Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comPalisade Bio, Inc. (NASDAQ:PALI) Short Interest Down 41.1% in MarchMarch 27, 2024 | finance.yahoo.comPalisade Bio Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 27, 2024 | investorplace.comPALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023March 20, 2024 | americanbankingnews.comFinancial Survey: Palisade Bio (NASDAQ:PALI) vs. BioCardia (NASDAQ:BCDA)February 15, 2024 | finance.yahoo.comPalisade Bio to Present at Digestive Disease Week (DDW) 2024February 15, 2024 | globenewswire.comPalisade Bio to Present at Digestive Disease Week (DDW) 2024February 13, 2024 | finanznachrichten.dePalisade Bio, Inc.: Palisade Bio Provides Corporate Update and Reiterates GuidanceMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.February 13, 2024 | marketwatch.comPalisade Names Donald Williams Chairman, Cuts Board Size in HalfFebruary 13, 2024 | finance.yahoo.comPalisade Bio Provides Corporate Update and Reiterates GuidanceFebruary 8, 2024 | finance.yahoo.comPalisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion LeadersJanuary 31, 2024 | msn.comFTC more `focused' on stopping bad deals after Amazon-iRobot - reportJanuary 30, 2024 | msn.comPalisade Bio Shares Updates and Drug Candidate ProgressJanuary 30, 2024 | finance.yahoo.comPalisade Bio Announces Exercise of Previously Issued Warrants for $2.5 MillionJanuary 30, 2024 | marketwatch.comPalisade Bio Shares Drop 23% After Warrants ExercisedJanuary 30, 2024 | finance.yahoo.comPalisade Bio Announces Exercise of Previously Issued Warrants for $2.5 MillionJanuary 29, 2024 | investorplace.comWhy Is Palisade Bio (PALI) Stock Up 100% Today?January 29, 2024 | finanznachrichten.dePalisade Bio, Inc.: Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis CongressJanuary 29, 2024 | msn.comPalisade stock soars 150% on cancelled offering, potential reverse splitJanuary 29, 2024 | seekingalpha.comPalisade stock soars 150% on canceled offering, potential reverse splitJanuary 29, 2024 | finance.yahoo.comPalisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis CongressJanuary 26, 2024 | marketwatch.comStocks to Watch: Palisade BioJanuary 26, 2024 | marketwatch.comPalisade Bio Up 40% After-Hours, Withdraws S-1 Filing and May Enact Reverse SplitJanuary 9, 2024 | finance.yahoo.comPalisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis CongressJanuary 9, 2024 | tmcnet.comPalisade Bio Selected for Poster Presentation at the 2024 Crohn's & Colitis CongressDecember 29, 2023 | msn.comPalisade Bio files to sell its sharesSee More Headlines Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today3/28/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PALI CUSIPN/A CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Target$8.75 High Stock Price Target$16.00 Low Stock Price Target$1.50 Potential Upside/Downside+2,092.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,260,000.00 Net MarginsN/A Pretax Margin-5,219.60% Return on Equity-84.70% Return on Assets-72.99% Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio6.14 Sales & Book Value Annual Sales$250,000.00 Price / Sales14.80 Cash FlowN/A Price / Cash FlowN/A Book Value$4.24 per share Price / Book0.09Miscellaneous Outstanding Shares9,270,000Free Float9,063,000Market Cap$3.70 million OptionableNot Optionable Beta1.33 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Ryker WillieSenior VP of Finance & Corporate ControllerKey CompetitorsAvalon GloboCareNASDAQ:ALBTKiromic BioPharmaNASDAQ:KRBPNanoString TechnologiesNASDAQ:NSTGQEloxx PharmaceuticalsNASDAQ:ELOXFinch Therapeutics GroupNASDAQ:FNCHView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 51,928 shares on 2/26/2024Ownership: 0.560%Donald Allen WilliamsBought 10,000 shares on 1/31/2024Total: $6,000.00 ($0.60/share)John David FinleyBought 15,000 shares on 9/27/2023Total: $8,100.00 ($0.54/share)Donald Allen WilliamsBought 20,000 shares on 9/27/2023Total: $10,800.00 ($0.54/share)Robert J. TrenschelSold 300 sharesTotal: $192.00 ($0.64/share)View All Insider TransactionsView All Institutional Transactions PALI Stock Analysis - Frequently Asked Questions Should I buy or sell Palisade Bio stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PALI shares. View PALI analyst ratings or view top-rated stocks. What is Palisade Bio's stock price target for 2024? 1 analysts have issued twelve-month target prices for Palisade Bio's stock. Their PALI share price targets range from $1.50 to $16.00. On average, they expect the company's stock price to reach $8.75 in the next twelve months. This suggests a possible upside of 2,092.4% from the stock's current price. View analysts price targets for PALI or view top-rated stocks among Wall Street analysts. How have PALI shares performed in 2024? Palisade Bio's stock was trading at $0.59 at the beginning of the year. Since then, PALI shares have decreased by 32.4% and is now trading at $0.3991. View the best growth stocks for 2024 here. Are investors shorting Palisade Bio? Palisade Bio saw a drop in short interest in March. As of March 15th, there was short interest totaling 45,200 shares, a drop of 41.1% from the February 29th total of 76,800 shares. Based on an average daily trading volume, of 2,610,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.5% of the company's stock are sold short. View Palisade Bio's Short Interest. When is Palisade Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our PALI earnings forecast. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) posted its earnings results on Thursday, November, 9th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.09. Who are Palisade Bio's major shareholders? Palisade Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.56%). Insiders that own company stock include Donald Allen Williams, John David Finley, Michael John Dawson, Robert J Trenschel, Robert J Trenschel and Thomas Hallam. View institutional ownership trends. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PALI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.